Vimta Labs Limited
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries.
What Vimta files
- Others56
- Investor Meet46
- Board Meeting14
- PPTs10
- Updates9
- Dividend/Bonus8
Vimta Labs kicked off FY27 with strong Q1 results. Total Income jumped 13.7% year-over-year to Rs 112.9 Cr. Net Profit (PAT) grew 11.4% YoY to Rs 21.0 Cr, while EBITDA rose 16.0% to Rs 41.1 Cr, maintaining a solid 36.4% margin. Basic EPS was Rs 4.7. The company holds top...
Vimta Labs reported robust performance for the quarter and the full fiscal year. For the quarter, total income grew 15.2% year-over-year to Rs 112 Cr, with PAT rising 15.2% to Rs 21.1 Cr. Quarterly EPS was Rs 4.7. For the full fiscal year, total income increased 19.5% YoY to Rs...
Vimta Labs reported its financial results for the quarter and nine-month period ending FY26. Total Income for Q3 reached Rs 100.5 Cr, a modest 0.4% YoY increase, with PAT at Rs 17.6 Cr (up 0.4% YoY). For the nine months (9M FY26), total income saw robust growth of 20.7% YoY...
Vimta Labs reported a strong H1 FY26 with total income up 26.6% YoY to ₹203.8 Cr and PAT up 25.5% YoY to ₹38.8 Cr. Q2 FY26 saw total income at ₹104.5 Cr (up 17.1% YoY) and PAT at ₹19.9 Cr (up 17.1% YoY), with an EPS of ₹4.5. The company...
**1. Financial Highlights:** Vimta Labs reported strong Q1 FY26 results with Total Income of ₹99.3 Cr, up 31.4% YoY. Profit After Tax (PAT) surged 36.0% YoY to ₹18.9 Cr, while EBITDA grew 33.1% YoY to ₹35.4 Cr, maintaining a healthy 35.7% margin. Capex for the quarter stood at ₹24.1 Cr....